Cartesian Therapeutics to be Acquired by 03 Life Sciences
Ticker: RNAC · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger
TL;DR
Cartesian Therapeutics is being bought by 03 Life Sciences, deal expected to close Q4 2024.
AI Summary
Cartesian Therapeutics, Inc. announced on September 25, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition marks a significant development for Cartesian Therapeutics.
Why It Matters
This acquisition by 03 Life Sciences could lead to new opportunities and resources for Cartesian Therapeutics' pipeline, potentially impacting the development and availability of its therapeutic candidates.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and the success of the integration and future development of Cartesian's pipeline by 03 Life Sciences are not guaranteed.
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- 03 Life Sciences (company) — Acquiring entity
- September 25, 2024 (date) — Date of agreement
- Fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the exact date of the definitive agreement for the acquisition?
The report states the date of the earliest event reported is September 25, 2024, indicating this is the date of the definitive agreement.
Who is acquiring Cartesian Therapeutics, Inc.?
Cartesian Therapeutics, Inc. is being acquired by 03 Life Sciences.
When is the acquisition expected to close?
The transaction is expected to close in the fourth quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the principal executive office address for Cartesian Therapeutics, Inc.?
The principal executive offices are located at 704 Quince Orchard Road, Gaithersburg, MD 20878.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-26 07:02:24
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
Filing Documents
- rnac-20240925.htm (8-K) — 27KB
- 0001453687-24-000110.txt ( ) — 149KB
- rnac-20240925.xsd (EX-101.SCH) — 2KB
- rnac-20240925_lab.xml (EX-101.LAB) — 22KB
- rnac-20240925_pre.xml (EX-101.PRE) — 13KB
- rnac-20240925_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 20, 2024, Cartesian Therapeutics, Inc. (the "Company") held its previously announced Special Meeting of Stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the Company approved the issuance of shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), upon conversion of the Company's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock"). The Automatic Conversion (as defined in the Certificate of Designation) of the Series B Preferred Stock occurred on September 25, 2024 at 5:00 p.m. Eastern Time pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the "Certificate of Designation"), of the Series B Preferred Stock. Following the Automatic Conversion of the Series B Preferred Stock, there are 23,893,525 shares of the Company's Common Stock issued and outstanding.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: September 26, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer